Yarrow Bioscience appointed Rebecca Frey as Chief Executive Officer and Tyler Zeronda as Chief Financial Officer, and expanded its board to six directors following the Closing.
| IndividualRebecca FreyTyler ZerondaSteven RyderLori PaytonRachael AlfordMona AshiyaSteven HoerterBill LundbergPeter SilvermanWilliam WhiteDavid DomzalskiIain StuartMutya Harsch | RoleChief Executive OfficerChief Financial OfficerChief Medical OfficerChief Development OfficerChief Operating OfficerDirectorDirectorDirector; Chair of the BoardDirectorDirectorVYNE President & CEO (resigned)VYNE Chief Scientific Officer (resigned)VYNE Chief Legal Officer & General Counsel (resigned) | Type of ChangeAppointedAppointedAppointedAppointedAppointedAppointedAppointedAppointedAppointedAppointedResigned; employment terminatedResigned; employment terminatedResigned; employment terminated | Effective DateJuly 27, 2026July 27, 2026July 27, 2026July 27, 2026July 27, 2026July 27, 2026July 27, 2026July 27, 2026July 27, 2026July 27, 2026July 27, 2026 (termination effective July 27, 2026)July 27, 2026 (termination effective July 27, 2026)July 27, 2026 (termination effective July 27, 2026) | ReasonNot disclosedNot disclosedNot disclosedNot disclosedNot disclosedOrbiMed designation notedNot disclosedNot disclosedNot disclosedNot disclosedTerminated at Closing; resignations not due to disagreementsTerminated at Closing; resignations not due to disagreementsTerminated at Closing; resignations not due to disagreements | Replacement InfoNot disclosedNot disclosedNot disclosedNot disclosedNot disclosedNot disclosedNot disclosedNot disclosedNot disclosedNot disclosedNot disclosedNot applicableNot applicable | Background DetailsExtensive biotech operating & investor experience; former Pre-Merger CEO; Pharm.D.; prior roles at RTW, Elm Street, Siduma, AlexionFormer CFO of VYNE; finance roles at Foamix, Aerie; CPA; MS in accountingFormer CMO at Rallybio; prior roles at Alexion, Pfizer; M.D.Former Principal Consultant and SVP Development at AlloVir; extensive R&D leadershipFormer Head CMC at Rallybio; prior roles at Alexion; Ph.D. in Biophysical ChemistryGeneral Partner at OrbiMed; Pre-Merger directorCEO of MBX Biosciences; extensive commercial leadershipPartner at Cold Spring Partners; former CEO of Merus; ChairFormer COO of Merus; legal background; J.D.Finance leader; former CFO roles at Akero; investment banking backgroundFormer VYNE CEO; eligible for separation benefits per offer letterFormer VYNE CSO; eligible for separation benefits per offer letterFormer VYNE CLO; eligible for separation benefits per offer letter | Board/Committee Role ChangesClass I director (term to 2028)Not disclosedClass I director (term to 2028)Not disclosedNot disclosedClass III director (term to 2027); OrbiMed designeeClass I director (term to 2028); Compensation Committee ChairClass II director (term to 2029); Board Chair; Governance Committee ChairClass II director (term to 2029)Class III director (term to 2027); Audit Committee ChairNot disclosedNot disclosedNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.